Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Matrix metalloproteinase and heparin-stimulated serine proteinase activities in post-prostate massage urine of men with prostate cancer.

Muñoz D, Serrano MK, Hernandez ME, Haller R, Swanson T, Slaton JW, Sinha AA, Wilson MJ.

Exp Mol Pathol. 2017 Dec;103(3):300-305. doi: 10.1016/j.yexmp.2017.11.015. Epub 2017 Nov 22.

PMID:
29175302
2.

Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice.

Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT, Ahmed K.

PLoS One. 2014 Oct 15;9(10):e109970. doi: 10.1371/journal.pone.0109970. eCollection 2014.

3.

Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.

Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M.

Eur Urol. 2014 Aug;66(2):265-72. doi: 10.1016/j.eururo.2014.02.036. Epub 2014 Feb 26.

PMID:
24630419
4.

Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial.

Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM.

J Urol. 2014 Jun;191(6):1721-7. doi: 10.1016/j.juro.2013.12.015. Epub 2013 Dec 14.

PMID:
24342144
5.

Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.

Wenner CA, Martzen MR, Lu H, Verneris MR, Wang H, Slaton JW.

Int J Oncol. 2012 Apr;40(4):905-13. doi: 10.3892/ijo.2011.1292. Epub 2011 Dec 12.

6.

Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.

Trembley JH, Unger GM, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton JW, Kren BT, Ahmed K.

Mol Cell Biochem. 2011 Oct;356(1-2):21-35. doi: 10.1007/s11010-011-0943-x. Epub 2011 Jul 15.

7.

Role for toll-like receptor 4 in TNF-alpha secretion by murine macrophages in response to polysaccharide Krestin, a Trametes versicolor mushroom extract.

Price LA, Wenner CA, Sloper DT, Slaton JW, Novack JP.

Fitoterapia. 2010 Oct;81(7):914-9. doi: 10.1016/j.fitote.2010.06.002. Epub 2010 Jun 13.

PMID:
20550956
8.

Association between lymph node density and disease specific survival in patients with penile cancer.

Svatek RS, Munsell M, Kincaid JM, Hegarty P, Slaton JW, Busby JE, Gaston KE, Spiess PE, Pagliaro LC, Tamboli P, Pettaway CA.

J Urol. 2009 Dec;182(6):2721-7. doi: 10.1016/j.juro.2009.08.029. Epub 2009 Oct 17.

PMID:
19837433
9.

Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP).

Wang X, Wilson MJ, Slaton JW, Sinha AA, Ewing SL, Pei D.

J Androl. 2009 May-Jun;30(3):259-74. doi: 10.2164/jandrol.108.006494. Epub 2009 Jan 8.

10.

WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth.

Wang L, Sloper DT, Addo SN, Tian D, Slaton JW, Xing C.

Cancer Res. 2008 Jun 1;68(11):4377-83. doi: 10.1158/0008-5472.CAN-07-6590.

11.

Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer.

Hamilton-Reeves JM, Rebello SA, Thomas W, Kurzer MS, Slaton JW.

Nutr Cancer. 2008;60(1):7-13. doi: 10.1080/01635580701586770.

PMID:
18444130
12.

Soy protein isolate increases urinary estrogens and the ratio of 2:16alpha-hydroxyestrone in men at high risk of prostate cancer.

Hamilton-Reeves JM, Rebello SA, Thomas W, Slaton JW, Kurzer MS.

J Nutr. 2007 Oct;137(10):2258-63.

PMID:
17885008
14.

CK2 signaling in androgen-dependent and -independent prostate cancer.

Wang G, Ahmad KA, Unger G, Slaton JW, Ahmed K.

J Cell Biochem. 2006 Oct 1;99(2):382-91. Review.

PMID:
16598768
15.

Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.

Canales BK, Anderson JK, Premoli J, Slaton JW.

J Urol. 2006 Jan;175(1):74-7.

PMID:
16406874
16.

Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy.

Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K.

Mol Cell Biochem. 2005 Jun;274(1-2):77-84.

PMID:
16342410
17.
18.

Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K.

Mol Cancer Res. 2004 Dec;2(12):712-21.

19.

Percutaneous renal stone extraction: in vitro study of retrieval devices.

Hoffman N, Lukasewycz SJ, Canales B, Botnaru A, Slaton JW, Monga M.

J Urol. 2004 Aug;172(2):559-61.

PMID:
15247729
20.

Protein kinase CK2 as regulator of cell survival: implications for cancer therapy.

Unger GM, Davis AT, Slaton JW, Ahmed K.

Curr Cancer Drug Targets. 2004 Feb;4(1):77-84. Review.

PMID:
14965269
21.

Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension.

Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ.

J Urol. 2004 Mar;171(3):1093-7.

PMID:
14767278
22.

Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors.

Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL.

Urology. 2004 Jan;63(1):46-50. Review.

PMID:
14751346
23.

Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.

Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, Dinney CP.

J Urol. 2004 Feb;171(2 Pt 1):570-4.

PMID:
14713761
24.

Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi.

Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP.

Urol Oncol. 2003 Sep-Oct;21(5):327-33.

PMID:
14670538
25.

Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults.

Rosser CJ, Slaton JW, Izawa JI, Levy LB, Dinney CP.

Urology. 2003 Jun;61(6):1151-5.

PMID:
12809885
26.

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.

Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP.

J Clin Oncol. 2003 Jun 15;21(12):2247-53.

PMID:
12805322
27.

Dipeptidylpeptidase IV activities in prostatic secretions.

Wilson MJ, Haller R, Slaton JW, Wasserman NF, Sinha AA.

Adv Exp Med Biol. 2003;524:257-60. No abstract available.

PMID:
12675248
28.

Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review.

Hoffman RM, MacDonald R, Slaton JW, Wilt TJ.

J Urol. 2003 Jan;169(1):210-5. Review.

PMID:
12478138
29.

Maximizing ureteroscope deflection: "play it straight".

Monga M, Dretler SP, Landman J, Slaton JW, Conradie MC, Clayman RV.

Urology. 2002 Nov;60(5):902-5.

PMID:
12429326
30.

The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.

Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T.

Clin Cancer Res. 2002 Jun;8(6):1863-70.

31.

Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.

Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP.

Clin Cancer Res. 2002 May;8(5):1253-64.

32.
33.
34.

Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.

Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL.

J Urol. 2002 Jan;167(1):65-70.

PMID:
11743277
35.

Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.

Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP.

Clin Cancer Res. 2001 Sep;7(9):2840-53.

36.

Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8.

Inoue K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP.

Oncol Rep. 2001 Sep-Oct;8(5):955-64.

PMID:
11496299
37.

P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy.

Slaton JW, Benedict WF, Dinney CP.

Urology. 2001 May;57(5):852-9. Review. No abstract available.

PMID:
11337281
38.

Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer.

Slaton JW, Morgenstern N, Levy DA, Santos MW Jr, Tamboli P, Ro JY, Ayala AG, Pettaway CA.

J Urol. 2001 Apr;165(4):1138-42.

PMID:
11257655
39.

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma.

Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP.

Am J Pathol. 2001 Feb;158(2):735-43.

40.

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.

Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R, Dinney CP.

Clin Cancer Res. 2000 Dec;6(12):4874-84.

41.

The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.

Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP.

Clin Cancer Res. 2000 Dec;6(12):4866-73.

42.

Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.

Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, Dinney CP.

Oncol Rep. 2001 Jan-Feb;8(1):9-15.

PMID:
11115562
43.

Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor.

Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P, Dinney CP.

Clin Cancer Res. 2000 Nov;6(11):4422-31.

44.
45.

Biosafety of in vivo adenovirus-p53 intravesical administration in mice.

Perrotte P, Wood M, Slaton JW, Wilson DR, Pagliaro L, Price RE, Dinney CP.

Urology. 2000 Jul;56(1):155-9.

PMID:
10869658
46.

Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.

Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP.

Clin Cancer Res. 2000 May;6(5):2104-19.

47.

Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer.

Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP.

Cancer Res. 2000 Apr 15;60(8):2290-9.

48.

Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma.

Balbay MD, Slaton JW, Trane N, Skibber J, Dinney CP.

Cancer. 1999 Dec 1;86(11):2212-6.

PMID:
10590359
49.
50.

Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion.

Donat SM, Slaton JW, Pisters LL, Swanson DA.

J Urol. 1999 Nov;162(5):1599-602.

PMID:
10524876

Supplemental Content

Loading ...
Support Center